Hosted on MSN1mon
AbbVie and Neomorph link on oncology/immunology glue degradersAbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.
Hosted on MSN1mon
AbbVie Inks a Deal With Neomorph for Molecular Glue DegradersFounded in 2020, Neomorph has been garnering interest from big pharma for its discovery platform. Last year, it signed separate multi-billion dollar partnerships with big-wigs Biogen BIIB and Novo ...
Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results